Core Viewpoint - The company is disposing of assets through its wholly-owned subsidiary, Qinhuangdao Tangren Pharmaceutical Chain Co., Ltd., by selling land use rights and building ownership for a total price of RMB 24 million [2][10][12]. Group 1: Transaction Overview - The transaction involves the sale of industrial land use rights and building ownership located in Qinhuangdao, with a total estimated transfer price of RMB 24 million [2][10]. - The transaction does not constitute a related party transaction or a major asset restructuring, and it was approved by the board of directors without the need for shareholder approval [3][8][18]. - The decision to close the Qinhuangdao logistics center and consolidate operations at the Hebei Tangshan logistics center is aimed at improving logistics efficiency and cost control [4][7][16]. Group 2: Asset Details - The asset being transferred includes a land use area of approximately 22,999.98 square meters and a building with a total area of 10,691.23 square meters [10][11]. - The assessed value of the building is approximately RMB 14.34 million, while the land use rights are valued at approximately RMB 9.66 million, totaling around RMB 23.99 million [11][12]. Group 3: Financial Impact - The disposal of the asset is expected to enhance asset utilization efficiency and improve the company's financial situation by recovering funds [16][17]. - The transaction is not anticipated to negatively impact the company's financial or operational status, nor will it harm the interests of shareholders [17][18]. Group 4: Transaction Process - The transaction will occur in three phases, with the first phase requiring a 30% deposit of the total price, followed by subsequent payments and the transfer of ownership [12][13][14]. - The final payment is due by November 30, 2025, and the asset transfer is scheduled for August 31, 2025 [13][14].